The Trend Is Your Friend And VRAL Is A Winner
June 26th, 2009 at 10:22 pm Posted by The Dean
To date, scientists have not been able to find a cure for HIV. The only drugs to be discovered are those that put the HIV virus on hold, offering many people longer, healthier lives. These drugs, called antiretrovirals (ARVs), also bring a variety of potential side effects some of which are difficult to live with and get worse over the years. Unfortunately, antiretroviral drugs can’t cure HIV — if you stop using them the virus comes back.
On the other hand, the VGV-1 is administered twice per week for a 16 week and there are no toxic side effects. After the 16 week regiment there is no need to take additional drugs.
There have been five human clinical trials with HIV infected individuals with varying viral load and CD4 levels in South Africa. These studies suggest that VGV-1 is well tolerated and associated with decreasing viral load.
VGV-1 also works through a mechanism that involves the use of the immune system, rather than attacking the virus itself. This means that VGV-1 may prove effective in treating other autoimmune diseases such as Lyme’s Disease and arthritis.
For investors this means multiple revenue streams from a number of patent protected drugs. The thymus nuclear protein compound is one of the most remarkable discoveries of mankind and I believe Haig Keledjian could become the second Nobel Prize winner beside Luc Montagnier on the team at Viral Genetics (VRAL).
The trend is your friend and the caliber of leadership at VRAL leads me to believe that its only a matter of time before VRAL is discovered as the next hot biotech discovery.
